General MedicationsINJECTIONStandard
LYMPHIR
DENILEUKIN DIFTITOX-CXDL
Standard Dose
300MCG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview LYMPHIR is listed in Drugs@FDA under application 761312 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient DENILEUKIN DIFTITOX-CXDL Form and strength INJECTABLE;INJECTION - 300MCG Sponsor CITIUS PHARMS Submission history Latest submission status date: 2024-08-07 00:00:00.
Structured Monograph
Clinical summary
Approval overview LYMPHIR is listed in Drugs@FDA under application 761312 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient DENILEUKIN DIFTITOX-CXDL Form and strength INJECTABLE;INJECTION - 300MCG Sponsor CITIUS PHARMS Submission history Latest submission status date: 2024-08-07 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.